Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620568
Title:
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Authors:
Pavel, M; Singh, S; Strosberg, J; Bubuteishvili-Pacaud, L; Degtyarev, E; Neary, M; Carnaghi, C; Tomasek, J; Wolin, E; Raderer, M; Lahner, H; Valle, Juan W ( 0000-0002-1999-0863 ) ; Pommier, R; Van Cutsem, E; Tesselaar, M; Fave, G; Buzzoni, R; Hunger, M; Eriksson, J; Cella, D; Ricci, J; Fazio, N; Kulke, M; Yao, J
Abstract:
In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint.
Affiliation:
Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
Citation:
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 2017 Lancet Oncol
Journal:
The Lancet Oncology
Issue Date:
21-Aug-2017
URI:
http://hdl.handle.net/10541/620568
DOI:
10.1016/S1470-2045(17)30471-0
PubMed ID:
28838862
Type:
Article
Language:
en
ISSN:
1474-5488
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPavel, Men
dc.contributor.authorSingh, Sen
dc.contributor.authorStrosberg, Jen
dc.contributor.authorBubuteishvili-Pacaud, Len
dc.contributor.authorDegtyarev, Een
dc.contributor.authorNeary, Men
dc.contributor.authorCarnaghi, Cen
dc.contributor.authorTomasek, Jen
dc.contributor.authorWolin, Een
dc.contributor.authorRaderer, Men
dc.contributor.authorLahner, Hen
dc.contributor.authorValle, Juan Wen
dc.contributor.authorPommier, Ren
dc.contributor.authorVan Cutsem, Een
dc.contributor.authorTesselaar, Men
dc.contributor.authorFave, Gen
dc.contributor.authorBuzzoni, Ren
dc.contributor.authorHunger, Men
dc.contributor.authorEriksson, Jen
dc.contributor.authorCella, Den
dc.contributor.authorRicci, Jen
dc.contributor.authorFazio, Nen
dc.contributor.authorKulke, Men
dc.contributor.authorYao, Jen
dc.date.accessioned2017-09-22T15:38:10Z-
dc.date.available2017-09-22T15:38:10Z-
dc.date.issued2017-08-21-
dc.identifier.citationHealth-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 2017 Lancet Oncolen
dc.identifier.issn1474-5488-
dc.identifier.pmid28838862-
dc.identifier.doi10.1016/S1470-2045(17)30471-0-
dc.identifier.urihttp://hdl.handle.net/10541/620568-
dc.description.abstractIn the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint.en
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleHealth-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germanyen
dc.identifier.journalThe Lancet Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.